PrEP Shines at the International AIDS Conference

There were a number of interesting PrEP (pre-exposure prophylaxis) presentations at the International AIDS Conference, which was held in Durban, South Africa, from July 18th to 22nd, 2016. Scott McCallister from Gilead presented 2016 CDC HIV transmission risk data in the U.S., an overview of 32 international studies of FTC/TDF (Truvada) usage for PrEP since it was licensed in the U.S. in 2012, and U.S. PrEP utilization data. Truvada, which is part of a cocktail regimen for people with HIV has demonstrated as much as a 90% effective rate in reducing the risk of HIV transmission when it is taken […]

New PrEP Data on Transgender Women from the IPREX Study

Researchers from the University of California in San Francisco (UCSF) unearthed new information about PrEP usage in transgender women by taking an innovative look at the new IPREX study data. The IPREX study was a 2010 French Canadian study in mostly negative gay and bisexual men that was the first to show the positive effect of emtricitabane plus tenofovir fumarate – which is combined in one pill known as Truvada – for HIV prevention. No such efficacy was found in transgender women because their initial numbers were too small to make any definitive findings. Only 29 people were initially identified […]